BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-10
DOI
10.1186/s40425-019-0744-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation
- (2018) Yu-Li Chen et al. CANCER LETTERS
- Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
- (2018) Belinda van Zyl et al. ENDOCRINE-RELATED CANCER
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
- (2018) Yiyi Yan et al. Frontiers in Immunology
- Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes
- (2018) Nai-Yun Sun et al. CANCER LETTERS
- High-concentration hydrogen protects mouse heart against ischemia/reperfusion injury through activation of thePI3K/Akt1 pathway
- (2017) Ouyang Chen et al. Scientific Reports
- Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes
- (2017) Qian Zhu et al. OncoImmunology
- PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
- (2017) Lihu Gu et al. PLoS One
- The Basis of Oncoimmunology
- (2016) A. Karolina Palucka et al. CELL
- TGF 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
- (2016) B. V. Park et al. Cancer Discovery
- Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
- (2015) L. Apetoh et al. ANNALS OF ONCOLOGY
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
- (2015) Z. Sun et al. CANCER RESEARCH
- A Threshold Level of Intratumor CD8 + T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
- (2015) Shin Foong Ngiow et al. CANCER RESEARCH
- IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients
- (2015) Yu-Li Chen et al. ENDOCRINE-RELATED CANCER
- Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
- (2014) M. Dai et al. CLINICAL CANCER RESEARCH
- B and T Lymphocyte Attenuator Regulates B Cell Receptor Signaling by Targeting Syk and BLNK
- (2014) A. C. Vendel et al. JOURNAL OF IMMUNOLOGY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Staging classification for cancer of the ovary, fallopian tube, and peritoneum
- (2013) Jaime Prat et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Microenvironmental regulation of tumor progression and metastasis
- (2013) Daniela F Quail et al. NATURE MEDICINE
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- B-cell receptor: from resting state to activate
- (2012) Bebhinn Treanor IMMUNOLOGY
- Therapeutic strategies in epithelial ovarian cancer
- (2012) Ayako Kim et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Therapeutic Potential of B and T Lymphocyte Attenuator Expressed on CD8 + T Cells for Contact Hypersensitivity
- (2012) Daiki Nakagomi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Depletion of Regulatory T Lymphocytes Reverses the Imbalance between Pro- and Anti-Tumor Immunities via Enhancing Antigen-Specific T Cell Immune Responses
- (2012) Yu-Li Chen et al. PLoS One
- Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
- (2012) X. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
- (2011) Yu-Li Chen et al. Molecular Oncology
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Slow Down and Survive: Enigmatic Immunoregulation by BTLA and HVEM
- (2010) Theresa L. Murphy et al. Annual Review of Immunology
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protective Roles of B and T Lymphocyte Attenuator in NKT Cell-Mediated Experimental Hepatitis
- (2009) Arifumi Iwata et al. JOURNAL OF IMMUNOLOGY
- A crucial role for HVEM and BTLA in preventing intestinal inflammation
- (2008) Marcos W. Steinberg et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation